Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2009 Results
Date:1/28/2010

.91 1.02 (11)% 4.42 3.82 16% =================== ========= ========= === ========= ========= === NM - not meaningful

Due to significant strategic actions taken by the company, financial results for 2009 and 2008 are presented on both a reported and a pro forma non-GAAP basis. Reported results were prepared in accordance with generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the period. Pro forma non-GAAP results exclude significant items described in the reconciliation tables and also assume the ImClone acquisition was completed January 1, 2008. The pro forma non-GAAP results are presented in order to provide additional insights into the underlying trends in the company's business. The company's 2010 financial guidance is also being provided on both a reported and a non-GAAP basis.

"Lilly's financial results in the fourth quarter completed a year of strong operational performance, highlighted by volume-based revenue gains, improved gross margins and quality earnings growth," said John C. Lechleiter Ph.D., Lilly's chairman and chief executive officer. "In 2009, we delivered solid financial results even as we continued to implement a series of actions aimed at speeding innovation to patients and delivering greater value to our customers. In 2010, we are well-positioned, through our new operating structure and development center of excellence, to maximize the value of our portfolio of products worldwide and advance the promising medicines currently in our clinical pipeline."

Significant Events Over the Last Three Months

  • The company restructured the collaboration agreement executed by Bristol-Myers Squibb and ImClone in 2001 to allow for the co-development and co-commercialization of the late-stage oncology molecule necitumumab (IMC-11F8), which is cur
    '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  A new analysis of Centers for Medicare and ... shows that 81 percent of seniors chose lower-cost preferred ... at certain pharmacies. The findings were released by ... now the foundation of Medicare Part D," said Pharmaceutical ...
(Date:1/23/2015)... WYNNEWOOD, Pa. , Jan. 23, 2015  MedScope ( ... has been nominated for a 2015 Connected World ... Personal Emergency Response System (mPERS), that can be used ... M2M technology partner.  In nominating MedScope, ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... 12, 2011 The TandemHeart circulatory support system has ... Medicare Administrative Contractor (MAC) serving over 1.3 million beneficiaries ... of the United States. "We are extremely ... of the TandemHeart system," said  Kraig McEwen, President and ...
... Endologix, Inc. (NASDAQ: ELGX ), developer and ... details relating to the release of its second quarter 2011 ... 2011 after the close of the market. Endologix ... at 5:00 p.m. ET / 2:00 p.m. PT to discuss ...
Cached Medicine Technology:TandemHeart Approved for Expanded Reimbursement 2Endologix to Report Second Quarter 2011 Financial Results on July 21, 2011 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The City of West ... 10 a.m., to commemorate the 42nd anniversary of the Supreme Court ... , “It’s been 42 years since the Roe vs. Wade decision ... still as present as ever,” said City of West Hollywood Councilmember ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Solutions, and Blue Shield of California Look to Promote ... 17 The State of California,s efforts to move ... shot in the arm today as The California Public ... Medco Health Solutions, Inc., and Blue Shield of California ...
... PRA ) said today that A. M. Best ... The Group,s debt rating was also upgraded to "BBB." The ... http://www.newscom.com/cgi-bin/prnh/20081024/PROASSURANCELOGO ) , ... outstanding financial performance," said W. Stancil Starnes, the President and ...
... TMC207 and the discovery of new drugs to treat ... new landmark collaboration between the Global Alliance for TB ... and Tibotec Inc., (Tibotec), a global pharmaceutical company, has ... response to the urgent need to accelerate the discovery ...
... Which Currently Dominate the Market, Will Decline by $1 ... Report from Decision Resources , , WALTHAM, Mass., ... leading research and advisory firms for pharmaceutical and healthcare ... anti-amyloid monoclonal antibodies, most notably Elan/Wyeth,s bapineuzumab and Eli ...
... As job loss, bankruptcy, and divorce skyrocket with the global ... to cope. The burden of these concerns can be agonizing, ... "7 Proven Steps: How to Defeat Stress Without Going Through ... many different kinds of stress life can throw your way. ...
... June 17 Modern technology is affecting the lives ... The unique needs of elders and their sometimes faraway ... technologies. Consider the problem of an elderly person living ... to visit the doctor or to eat a meal. ...
Cached Medicine News:Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 2Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 3Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 4Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 5Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 6Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 7Health News:A. M. Best Upgrades ProAssurance Group to 'A' (Excellent) 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6Health News:New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 3Health News:New Technology Assists Independent Seniors 2
... test is an immunochromatography based one step ... determination of THC and its metabolites in ... in human urine above a cut-off,level of ... has not been evaluated in the point ...
... RapidBZO test is an immunochromatography based ... is,designed for qualitative determination of Benzodiazepines ... above a cut-off level of 300 ... been,evaluated in the point of care ...
... ACL TOP is a fully ... volume labs maximize labor resources and ... provides clotting, chromogenic and immunoturbidimetric testing ... routine and specialty assays. It's also ...
... membrane parasite soluble lysate ... as antigen. Since this ... than the recombinant kit, ... use two ELISA techniques ...
Medicine Products: